Netupitant-Palonosetron FDC Global Market Report 2025

The netupitant-palonosetron fixed dose combination (FDC) market size has grown strongly in recent years. It will grow from $351.5 billion in 2024 to $384.5 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. Growth during the historic period was driven by the rising adoption of combination antiemetic therapies, greater awareness among oncologists, a growing number of cancer cases, increasing clinical evidence of safety and efficacy, and improved access to cancer treatment in emerging markets.

The netupitant-palonosetron fixed dose combination (FDC) market size is expected to see strong growth in the next few years. It will grow to $555.45 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. Key factors contributing to this growth include increased focus on enhancing quality of life during chemotherapy, the rising trend of home-based chemotherapy treatment, demand for user-friendly antiemetic regimens, and the preference for oral fixed-dose combinations over multiple separate medications. Notable trends in the forecast period include advances in therapeutic options, development of dual-action formulations, innovations in technology-driven drug formulation, creation of oral-disintegrating dosage forms, and improved control of multiday emesis.

The increasing prevalence of cancer is expected to propel the growth of the netupitant-palonosetron fixed-dose combination (FDC) market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The increasing prevalence of cancer is due to lifestyle choices such as poor diet, smoking, physical inactivity, and excessive alcohol consumption. Netupitant-palonosetron fixed-dose combination (FDC) enhances cancer treatment by combining two effective antiemetic agents, preventing both acute and delayed chemotherapy-induced nausea and vomiting. They improve patient comfort and adherence to treatment, supporting better overall care outcomes. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, the number of cancer cases diagnosed in Australia reached 160,570 in 2022, marking an increase of 3,789 cases from 156,781 in 2021. Therefore, the increasing prevalence of cancer is driving the growth of the netupitant-palonosetron fixed-dose combination (FDC) market.

The rising demand for oral drugs is expected to propel the growth of the netupitant-palonosetron fixed-dose combination (FDC) market going forward. Oral drugs refer to medications that are taken by mouth and absorbed through the digestive system to treat or prevent various health conditions. The rising demand for oral drugs is due to their convenience and ease of administration, allowing patients to self-administer medication without the need for professional assistance. Netupitant-palonosetron FDC enhances the effectiveness of oral drugs by preventing nausea and vomiting, thereby improving patient compliance and treatment outcomes. For instance, in October 2022, according to the Centers for Disease Control and Prevention, a US-based government administration, the dispensing of oral antivirals rose by 57%, increasing from 643 per 100,000 persons between April 24 and May 21, 2022, to 1,012 per 100,000 persons between July 31 and August 28, 2022. Therefore, the rising demand for oral drugs drives the growth of the netupitant-palonosetron fixed-dose combination (FDC) market.

Major companies operating in the netupitant-palonosetron fixed-dose combination (FDC) market are focusing on developing advanced formulation products, such as ready-to-use intravenous formulations, to enhance patient convenience and treatment efficacy. Ready-to-use intravenous formulations are pre-prepared, sterile drug solutions that eliminate the need for dilution or mixing, helping netupitant-palonosetron fixed-dose combination (FDC) by simplifying administration and reducing preparation errors. For instance, in June 2024, Helsinn Group, a Switzerland-based pharmaceutical company, launched AKYNZEO (fosnetupitant/palonosetron) injection, a ready-to-use vial made available in the United States. This new formulation is designed to simplify preparation and administration for healthcare providers, enhancing convenience in clinical settings. The injection requires no reconstitution or dilution and can be infused directly from the vial using an integrated hanging strap.

Major players in the netupitant-palonosetron fixed dose combination (fdc) market are Taiho PharmaceuticalTaiho Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Zhejiang Tiantai Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Limited, Helsinn Group, Heron Therapeutics Inc., Metrochem API Private Limited, Mundipharma Pty Ltd, Guangzhou Tosun Pharmaceutical Co. Ltd., Tesaro Inc., Accord Healthcare Ltd., Century Pharmaceuticals Ltd., Specialised Therapeutics Australia Pty Ltd., Aark Pharmaceuticals Ltd., Chemicea Pharmaceuticals Pvt. Ltd., Teva Pharmaceutical Industries Ltd.

North America was the largest region in the netupitant-palonosetron fixed dose combination (FDC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in netupitant-palonosetron fixed dose combination (FDC) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the netupitant-palonosetron fixed dose combination (FDC) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The netupitant-palonosetron fixed-dose combination (FDC) is a pharmaceutical formulation that integrates two active ingredients - netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron, a serotonin (5-HT3) receptor antagonist - into a single dose. This combination is mainly used to prevent both acute and delayed nausea and vomiting associated with chemotherapy. Netupitant functions by blocking the action of substance P at NK1 receptors in the brain, while palonosetron inhibits serotonin activity at 5-HT3 receptors, which are central to the development of chemotherapy-induced nausea and vomiting (CINV).

The primary product types in the netupitant-palonosetron fixed-dose combination (FDC) market include netupitant, palonosetron, and the fixed-dose combination (FDC) itself. Netupitant is used to prevent chemotherapy-induced nausea and vomiting by targeting substance P/neurokinin 1 (NK1) receptors. It is administered via oral, intravenous (IV), and sublingual routes, and is used in the management of chemotherapy-induced nausea and vomiting (CINV), postoperative nausea and vomiting (PONV), and general nausea. Distribution channels include hospitals, retail pharmacies, online pharmacies, and specialty clinics.

The netupitant-palonosetron fixed dose combination (FDC) market research report is one of a series of new reports that cover netupitant-palonosetron fixed dose combination (FDC) market statistics, including the netupitant-palonosetron fixed dose combination (FDC) industry's global market size, regional shares, competitors with the netupitant-palonosetron fixed dose combination (FDC) market share, detailed netupitant-palonosetron fixed dose combination (FDC) market segments, market trends and opportunities, and any further data you may need to thrive in the netupitant-palonosetron fixed dose combination (FDC) market. This netupitant-palonosetron fixed dose combination (FDC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The netupitant-palonosetron fixed dose combination (FDC) market consists of sales of oral capsules, injectable formulations, premixed infusion bags, combination therapy kits, and generic versions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.